Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many tissues. The primary physiological substrate of this enzyme is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin.
The global Urokinase industry has a rather high concentration. The major manufacturers are concentrated in China, such as NDPharm, Wanhua Biochem, Jiangxi Haoran Bio-Pharma and Jiangsu Aidea Pharmaceutica. At present, NDPharm is the world leader, holding 61.93% production market share in 2016.
In 2016, the global Urokinase consumption market is led by China and China is the largest region consumption market, accounting for about 18.58% of global consumption of Urokinase.
Urokinase downstream is wide and recently Urokinase has acquired increasing significance in various fields of Hospital, Clinic and others. Globally, the Urokinase market is mainly driven by growing demand for Hospital. Hospital accounts for nearly 78.59% of total downstream consumption of Urokinase in global.
The report offers detailed coverage of Urokinase industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Urokinase by geography. The report splits the market size, by volume and value, on the basis of application type and geography.
The report forecast global Urokinase market to grow to reach xxx Million USD in 2020 with a CAGR of xx% during the period 2021-2025.
First, this report covers the present status and the future prospects of the global Urokinase market for 2015-2025.
And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].
Key Companies
NDPharm
Wanhua Biochem
Jiangxi Haoran Bio-Pharma
Jiangsu Aidea Pharmaceutical
At the same time, we classify Urokinase according to the type, application by geography. More importantly, the report includes major countries market based on the type and application.
Market Segment as follows:
Market by Order Type
Urokinase Powder
Urokinase Solution
Market by Application
Hospital
Clinic
Others
By Region
Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America[United States, Canada, Mexico]
Middle East & Africa[GCC, North Africa, South Africa]
South America[Brazil, Argentina, Columbia, Chile, Peru]
The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the Urokinase market for the forecast period 2021 - 2025?
• What are the driving forces in the Urokinase market for the forecast period 2021 - 2025?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the Urokinase industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?